Abstract:Spinocerebellar ataxia type 3 (SCA3), a neurodegenerative disorder caused by a CAG expansion in the gene, is the most common spinocerebellar ataxia subtype worldwide. Currently, there is no therapy to stop or prevent disease progression. Promising therapeutic strategies are emerging, but their translation into clinical practice requires sensitive and reliable biomarkers. Blood circulating extracellular vesicles constitute a promising source of biomarkers with potential to track alterations of the central nervous system due to their ability to cross the blood brain barrier. Here, we perform sequencing analysis of small RNAs from plasma-derived extracellular vesicles from SCA3 mutation carriers (10 pre-ataxic and 10 ataxic) and 12 control subjects to identify potential RNA biomarker candidates for this disease. Data showed that plasma-derived extracellular vesicles from ataxic SCA3 mutation carriers are enriched in mitochondrial, nuclear, and nucleolar RNA biotypes compared to pre-ataxic and control subjects. Moreover, ataxic mutation carriers could be discriminated from control and pre-ataxic subjects based on the miRNAs or piRNAs content, but not tRNA. Furthermore, we identified a subset of differentially expressed miRNAs and piRNAs that clearly differentiate ataxic mutation carriers from pre-ataxic and control subjects. These findings open new avenues for further investigation on the role of these RNAs in the pathogenesis of SCA3 and their potential as biomarkers for this disease.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to identify potential RNA biomarkers that can distinguish spinocerebellar ataxia type 3 (SCA3) mutation carriers (including the pre - ataxia stage and the ataxia stage) from healthy control groups. Specifically, by analyzing small non - coding RNAs (such as miRNA and piRNA) in plasma - derived extracellular vesicles, the study aims to discover whether these RNAs can be used as biomarkers for SCA3 for early diagnosis of the disease or monitoring of disease progression. In addition, the study also explores the possible roles of these differentially expressed RNAs in the pathological process of SCA3. ### Main research objectives: 1. **Identify potential biomarkers**: By analyzing small non - coding RNAs in plasma - derived extracellular vesicles, identify RNA biomarkers that can distinguish SCA3 mutation carriers (pre - ataxia and ataxia stages) from healthy control groups. 2. **Explore the pathological role of RNA**: Study the potential functions of these differentially expressed RNAs in the pathological process of SCA3, especially how they participate in biological processes such as cell stress response, tissue development, and protein stability regulation. ### Research methods: - **Sample collection**: Collect plasma samples from SCA3 mutation carriers (pre - ataxia and ataxia stages) and healthy control groups. - **Extracellular vesicle isolation**: Use size - exclusion chromatography (SEC) to isolate extracellular vesicles from plasma. - **RNA extraction and sequencing**: Extract total RNA from the isolated extracellular vesicles and perform small RNA sequencing. - **Data analysis**: Filter, align, and count genes in the sequencing data, and use the DESeq2 software package to perform differential expression analysis to identify RNAs that are significantly differentially expressed between different groups. ### Main findings: - **Differences in RNA abundance**: Compared with the healthy control group and the pre - ataxia group, the extracellular vesicles in the ataxia group are rich in mitochondrial, nuclear, and nucleolar RNAs. - **Differential expression of miRNA**: 53 miRNAs that are differentially expressed between the ataxia group and the healthy control group were identified, and 6 of these miRNAs are also differentially expressed between the pre - ataxia group and the healthy control group. - **Differential expression of piRNA**: 12 piRNAs that are differentially expressed between the ataxia group and the healthy control group were identified, and these piRNAs can effectively distinguish the ataxia group from the pre - ataxia group and the healthy control group. - **Functional enrichment analysis**: The target genes of the differentially expressed miRNAs are mainly involved in cell stress response, tissue development, protein stability regulation, and miRNA processes. ### Conclusion: This study successfully identified a set of RNA biomarkers, especially miRNA and piRNA, that can distinguish SCA3 mutation carriers from healthy control groups in plasma - derived extracellular vesicles. These findings provide new approaches for the early diagnosis and disease progression monitoring of SCA3 and lay the foundation for further research on the roles of these RNAs in the pathological process of SCA3.

Small non-coding RNA content in plasma-derived extracellular vesicles distinguish ataxic SCA3 mutation carriers from pre-ataxic and control subjects

Blood levels of neurofilament light are associated with disease progression in a mouse model of spinocerebellar ataxia type 3

PolyQ-expanded ataxin-3 protein levels in peripheral blood mononuclear cells correlate with clinical parameters in SCA3: a pilot study

Blood and cerebellar abundance of ATXN3 splice variants in spinocerebellar ataxia type 3/Machado-Joseph disease

A Systematic Review of Their Potential Uses in Disease Staging and Treatment Assessment

Recent advances in understanding dominant spinocerebellar ataxias from clinical and genetic points of view

Systematic assessment of plasma biomarkers in spinocerebellar ataxia

Longitudinal Changes of Clinical, Imaging, and Fluid Biomarkers in Preataxic and Early Ataxic Spinocerebellar Ataxia Type 2 and 7 Carriers

Clinically Meaningful Magnetic Resonance Endpoints Sensitive to Preataxic Spinocerebellar Ataxia Types 1 and 3

Neurofilament light chain is a promising serum biomarker in spinocerebellar ataxia type 3

Multimodal, Longitudinal Profiling of SCA1 Identifies Predictors of Disease Severity and Progression

Spinocerebellar Ataxia Type 3 Pathophysiology—Implications for Translational Research and Clinical Studies

Sensitivity of Advanced Magnetic Resonance Imaging to Progression over Six Months in Early Spinocerebellar Ataxia

Synaptic Loss in Spinocerebellar Ataxia Type 3 Revealed by SV2A Positron Emission Tomography

Novel genotype–phenotype correlations, differential cerebellar allele-specific methylation, and a common origin of the (ATTTC)n insertion in spinocerebellar ataxia type 37

Widespread alternative splicing dysregulation occurs presymptomatically in CAG expansion spinocerebellar ataxias

Age-dependent somatic expansion of the CAG repeat in the blood and buccal cell DNA of individuals with spinocerebellar ataxia type 3

Autosomal dominant cerebellar ataxias: new genes and progress towards treatments

An insight into advances in the pathogenesis and therapeutic strategies of spinocerebellar ataxia type 3

Single-nuclei RNA sequencing uncovers non-cell autonomous changes in cerebellar astrocytes and oligodendrocytes that may contribute to Spinocerebellar Ataxia Type 1 (SCA1) pathogenesis

Age-dependent somatic expansion of the ATXN3 CAG repeat in the blood and buccal swab DNA of individuals with spinocerebellar ataxia type 3/Machado-Joseph disease